Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS

This monocentric prospective study of patient suffering from Amyotrophic lateral sclerosis (ALS) aims to evaluate the prognosis and diagnostic potential of both Neurofilament-Light (Nf-L) and neuroinflammatory biomarkers in serum and CSF. Candidate markers levels were measured using multiplex method...

Descripción completa

Detalles Bibliográficos
Autores principales: Brodovitch, Alexandre, Boucraut, José, Delmont, Emilien, Parlanti, Amandine, Grapperon, Aude-Marie, Attarian, Shahram, Verschueren, Annie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803734/
https://www.ncbi.nlm.nih.gov/pubmed/33436881
http://dx.doi.org/10.1038/s41598-020-80370-6
_version_ 1783636006928384000
author Brodovitch, Alexandre
Boucraut, José
Delmont, Emilien
Parlanti, Amandine
Grapperon, Aude-Marie
Attarian, Shahram
Verschueren, Annie
author_facet Brodovitch, Alexandre
Boucraut, José
Delmont, Emilien
Parlanti, Amandine
Grapperon, Aude-Marie
Attarian, Shahram
Verschueren, Annie
author_sort Brodovitch, Alexandre
collection PubMed
description This monocentric prospective study of patient suffering from Amyotrophic lateral sclerosis (ALS) aims to evaluate the prognosis and diagnostic potential of both Neurofilament-Light (Nf-L) and neuroinflammatory biomarkers in serum and CSF. Candidate markers levels were measured using multiplex method in serum of 60 ALS patients, 94 healthy controls of 43 patients suffering from Inflammatory Peripheral Neuropathies (IPN). A comparative CSF analysis was performed for 20 ALS and 17 IPN patients. Among the altered biomarkers, CSF Nf-L level remains the best marker of ALS severity, while serum levels correlate strongly with disease progression. The combination of Nf-L and ICAM-1 concentrations in the CSF and IFN-γ concentration in the serum differentiate ALS patients from IPN patients with improved sensibility and specificity relative to individual biomarkers. A cutoff value of 0.49 for the fitted values of these 3 biomarkers discriminate ALS from IPN patients with a specificity of 100% (78.20–100%) and a sensibility of 85.71% (57.19–98.22%) with an AUC of 0.99 ± 0.01. The measure of Nf-L and neuroinflammatory biomarkers in CSF and serum can be useful biomarkers panel in the differential diagnosis of ALS.
format Online
Article
Text
id pubmed-7803734
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78037342021-01-13 Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS Brodovitch, Alexandre Boucraut, José Delmont, Emilien Parlanti, Amandine Grapperon, Aude-Marie Attarian, Shahram Verschueren, Annie Sci Rep Article This monocentric prospective study of patient suffering from Amyotrophic lateral sclerosis (ALS) aims to evaluate the prognosis and diagnostic potential of both Neurofilament-Light (Nf-L) and neuroinflammatory biomarkers in serum and CSF. Candidate markers levels were measured using multiplex method in serum of 60 ALS patients, 94 healthy controls of 43 patients suffering from Inflammatory Peripheral Neuropathies (IPN). A comparative CSF analysis was performed for 20 ALS and 17 IPN patients. Among the altered biomarkers, CSF Nf-L level remains the best marker of ALS severity, while serum levels correlate strongly with disease progression. The combination of Nf-L and ICAM-1 concentrations in the CSF and IFN-γ concentration in the serum differentiate ALS patients from IPN patients with improved sensibility and specificity relative to individual biomarkers. A cutoff value of 0.49 for the fitted values of these 3 biomarkers discriminate ALS from IPN patients with a specificity of 100% (78.20–100%) and a sensibility of 85.71% (57.19–98.22%) with an AUC of 0.99 ± 0.01. The measure of Nf-L and neuroinflammatory biomarkers in CSF and serum can be useful biomarkers panel in the differential diagnosis of ALS. Nature Publishing Group UK 2021-01-12 /pmc/articles/PMC7803734/ /pubmed/33436881 http://dx.doi.org/10.1038/s41598-020-80370-6 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Brodovitch, Alexandre
Boucraut, José
Delmont, Emilien
Parlanti, Amandine
Grapperon, Aude-Marie
Attarian, Shahram
Verschueren, Annie
Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS
title Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS
title_full Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS
title_fullStr Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS
title_full_unstemmed Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS
title_short Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS
title_sort combination of serum and csf neurofilament-light and neuroinflammatory biomarkers to evaluate als
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803734/
https://www.ncbi.nlm.nih.gov/pubmed/33436881
http://dx.doi.org/10.1038/s41598-020-80370-6
work_keys_str_mv AT brodovitchalexandre combinationofserumandcsfneurofilamentlightandneuroinflammatorybiomarkerstoevaluateals
AT boucrautjose combinationofserumandcsfneurofilamentlightandneuroinflammatorybiomarkerstoevaluateals
AT delmontemilien combinationofserumandcsfneurofilamentlightandneuroinflammatorybiomarkerstoevaluateals
AT parlantiamandine combinationofserumandcsfneurofilamentlightandneuroinflammatorybiomarkerstoevaluateals
AT grapperonaudemarie combinationofserumandcsfneurofilamentlightandneuroinflammatorybiomarkerstoevaluateals
AT attarianshahram combinationofserumandcsfneurofilamentlightandneuroinflammatorybiomarkerstoevaluateals
AT verschuerenannie combinationofserumandcsfneurofilamentlightandneuroinflammatorybiomarkerstoevaluateals